Table 3.
Distribution of Pain-Free Responses: 2 Hours and Sustained 2–24 Hours
| 2 hours | 2–24 hours | ||||||
|---|---|---|---|---|---|---|---|
| Number of menstrual symptoms at 30 minutes | Treatment group | No | Yes | Odds ratio | No | Yes | Odds ratio |
| 0 | Placebo | 76 | 36 | 3.92a | 88 | 24 | 3.08a |
| Suma-Nap | 36 | 67 | 56 | 47 | |||
| 1 | Placebo | 62 | 10 | 5.96a | 66 | 6 | 7.7a |
| Suma-Nap | 26 | 25 | 30 | 21 | |||
| 2 | Placebo | 36 | 7 | 4.73a | 40 | 3 | 8.0a |
| Suma-Nap | 25 | 23 | 30 | 18 | |||
| 3 | Placebo | 31 | 10 | 1.14 | 36 | 6 | 0.91 |
| Suma-Nap | 28 | 10 | 33 | 5 | |||
| 4 | Placebo | 18 | 4 | 1.29 | 20 | 2 | 1.25 |
| Suma-Nap | 28 | 8 | 32 | 4 | |||
| 5 | Placebo | 15 | 4 | 3.28 | 15 | 4 | 2.5 |
| Suma-Nap | 8 | 7 | 9 | 6 | |||
| 6 | Placebo | 8 | 1 | 0.8 | 9 | 0 | 1 |
| Suma-Nap | 10 | 1 | 11 | 0 | |||
a
p value<0.05
Suma-Nap, sumatriptan-naproxen.